CD38 and hematologic disorder: Anti-CD38 antibodies exhibited strong ADCC activity against cells associated with hematological malignancies (Daudi, L-1236, Raji, and NCI-H929 cell lines) in a concentration-dependent manner via FcR-TANK (effector).